Other Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26 pharminent April 2, 2026
M&A / Deals Biocytogen and Sihuan partner to advance new therapeutics for weight loss pharminent April 2, 2026
M&A / Deals Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets pharminent April 1, 2026
Regulatory FDA approves Lilly obesity pill, triggering battle with Novo Nordisk pharminent April 1, 2026
Regulatory Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry pharminent April 1, 2026
Regulatory FDA Approves First New Molecular Entity Under National Priority Voucher Program pharminent April 1, 2026
Clinical Data Viridian reports positive results from elegrobart phase 3 trial pharminent April 1, 2026
Clinical Data ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D pharminent April 1, 2026
M&A / Deals Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes pharminent April 1, 2026
M&A / Deals Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B pharminent April 1, 2026
Regulatory FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries pharminent April 1, 2026
Regulatory FDA, after turbulent year, leaves drugmakers guessing on its direction pharminent April 1, 2026
Policy / Pricing A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma pharminent April 1, 2026
Clinical Data ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose pharminent April 1, 2026
Clinical Data ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit pharminent April 1, 2026
Regulatory S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD pharminent March 31, 2026
M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout pharminent March 31, 2026
M&A / Deals Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy pharminent March 31, 2026
Clinical Data PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease pharminent March 31, 2026
M&A / Deals Biogen, with $5.6B Apellis buy, builds out immunology offerings pharminent March 31, 2026
